Ability Biologics: Revolutionizing Antibody Therapeutics
July 2, 2024, 9:35 pm
Ability Biologics, a Montreal-based cell targeting company, recently closed an impressive $18 million in seed funding. Led by CEO Giles Day, the company is on a mission to develop potent and selective antibody therapeutics for areas of great unmet need. With their innovative AbiLeap™ discovery engine, Ability Biologics is combining AI technology with an extensive database of antigen-antibody interactions to create fully human, logic-gated antibodies that respond to environmental signals within the cellular microenvironment.
This funding round, led by Amplitude Ventures and joined by FTQ, Investissement Québec, Charles River Laboratories, Theodorus, and Alexandria Venture Investments, will allow Ability Biologics to expand its operations and further advance its R&D sector. The company's unique approach to antibody development sets them apart in the industry, as they focus on addressing complex biology challenges and tackling issues like on-target, off-tissue toxicity.
Giles Day, the Co-founder and CEO of Ability Biologics, emphasized the importance of developing antibodies with broad therapeutic windows and enhanced specificity. By overlaying multiple approaches in a single molecule, the company aims to create potent therapeutics that are easier to manufacture, store, and administer. This strategic use of tried and tested IgG formats minimizes risks and maximizes therapeutic impact.
Amplitude Ventures, a founding investor in Ability Biologics, recognizes the potential of the company's proprietary platform in rapidly developing selective and potent biotherapeutics. Dion Madsen, CFA, Co-founder and Partner at Amplitude Ventures, highlights the significance of leveraging advanced technologies like artificial intelligence to enhance patient outcomes and revolutionize the treatment of various diseases, including cancer.
Investissement Québec, another key investor in Ability Biologics, acknowledges the importance of supporting innovative biotech companies like Ability in harnessing cutting-edge technologies for the development of life-saving therapies. Bicha Ngo, President and CEO of Investissement Québec, emphasizes the critical role that Québec's expertise in antibody development plays in advancing the field of biotechnology and improving healthcare outcomes for patients.
In a rapidly evolving life science and biotech sector, Ability Biologics stands out as a trailblazer in the field of antibody therapeutics. With their commitment to innovation, strategic partnerships, and groundbreaking technology, the company is poised to make a significant impact in the treatment of complex diseases and revolutionize the way we approach antibody-based therapies.
This funding round, led by Amplitude Ventures and joined by FTQ, Investissement Québec, Charles River Laboratories, Theodorus, and Alexandria Venture Investments, will allow Ability Biologics to expand its operations and further advance its R&D sector. The company's unique approach to antibody development sets them apart in the industry, as they focus on addressing complex biology challenges and tackling issues like on-target, off-tissue toxicity.
Giles Day, the Co-founder and CEO of Ability Biologics, emphasized the importance of developing antibodies with broad therapeutic windows and enhanced specificity. By overlaying multiple approaches in a single molecule, the company aims to create potent therapeutics that are easier to manufacture, store, and administer. This strategic use of tried and tested IgG formats minimizes risks and maximizes therapeutic impact.
Amplitude Ventures, a founding investor in Ability Biologics, recognizes the potential of the company's proprietary platform in rapidly developing selective and potent biotherapeutics. Dion Madsen, CFA, Co-founder and Partner at Amplitude Ventures, highlights the significance of leveraging advanced technologies like artificial intelligence to enhance patient outcomes and revolutionize the treatment of various diseases, including cancer.
Investissement Québec, another key investor in Ability Biologics, acknowledges the importance of supporting innovative biotech companies like Ability in harnessing cutting-edge technologies for the development of life-saving therapies. Bicha Ngo, President and CEO of Investissement Québec, emphasizes the critical role that Québec's expertise in antibody development plays in advancing the field of biotechnology and improving healthcare outcomes for patients.
In a rapidly evolving life science and biotech sector, Ability Biologics stands out as a trailblazer in the field of antibody therapeutics. With their commitment to innovation, strategic partnerships, and groundbreaking technology, the company is poised to make a significant impact in the treatment of complex diseases and revolutionize the way we approach antibody-based therapies.